Warnex also extended to Jan. 31, 2018, its existing lease for its headquarters at 3885 Industriel Blvd. in Laval.
Sirtex Wins FDA Approval to Start Manufacturing at New Wilmington, Mass., Plant
Sirtex Medical can begin production at a newly built manufacturing plant in Wilmington, Mass., following a recent approval by the US Food and Drug Administration.
The facility can now begin supplying the company's SIR-Spheres microsphere doses to US treatment centers that will use them to offer Selective Internal Radiation Therapy, or SIRT, for inoperable liver cancer, the company said. The Wilmington plant can produce up to 200 doses a week, Sirtex said.
Wilmington is one of two manufacturing sites for Sirtex; the other is in Australia. Sirtex is headquartered in Sydney.
Medical R&D Company Launched Within Qatar Science & Tech Park
Scientific Medical Applied Research & Development, which calls itself Qatar’s first biotechnology and medical research company, has been launched within the Qatar Science & Technology Park. SMARD will develop diagnostic tools and treatments for diseases, especially those afflicting populations in the Middle East and North Africa
SMARD is a subsidiary of the German companies KMG AG and iSIMA, which collaborate with universities in Tübingen and other clinics and universities in Germany and Austria. SMARD will expand those collaborations to include Cairo University and Menoufeya University in Egypt, as well as other international hospitals and R&D institutes.
Clinical Trial Services Provider Expands With New São Paulo, Brazil, Office
MDS Pharma Services, a clinical trial services provider headquartered in King of Prussia, Pa., has opened an office in São Paulo, Brazil.
The company said its new office will allow it to offer clients access to more than 237,000 physicians and more than 46,000 health institutions.
The new office joins nearly two dozen other late-stage clinical trial management offices run by MDS in 21 countries in Africa, Asia, Europe, Latin America and North America.
Washington, DC, Biotech Eyes Move to Maryland for New Headquarters
Washington, DC-based biotech Bioscan is searching sites along Interstate 270 in Montgomery County, Md., for a new expanded headquarters, the Baltimore Business Journal reported.
Bioscan now occupies 7,500 square feet on MacArthur Blvd., and has leased temporary lab space in Montgomery County for more than a year. Bioscan is now seeking 11,000 square feet there, after being headquartered in Washington since it was founded more than 20 years ago.
"We haven't really pushed [staying in DC] hard, because we didn't think there was any suitable space." Seth Shulman, founder, chairman and chief scientific officer for Bioscan, told the newspaper. He noted that Bioscan’s current HQ is zoned as commercial, rather than research and development or industrial: “The zoning in Washington has always been rather ill-defined,” he said.
Developer Asks Port St. Lucie, Fla., to Annex Land for Biotech Park
Lulfs Groves, a Lake Grove, Fla.-based developer, has asked the city of Port St. Lucie, Fla., to annex 465 acres of agricultural land it bought in December, then rezone it to allow for a regional business park with lower-cost land for biotech spinoffs and manufacturing plants, the Palm Beach Post reported.
Lulfs Grove – owned by Brian Lulf, owner of Atlas Peat and Soil in Boynton Beach, Fla. – wants to build 2.4 million square feet of industrial space, 500 homes, and up to 600,000 square feet of space for retail, office, and institutional use. Lulfs Grove hopes to capitalize on the site’s location midway between the Florida Center for Innovation, the life sciences campus within the Tradition master-planned mixed-use community; and a research campus planned by St. Lucie County.
Hence Lulfs Grove’s $9.29 million purchase of the parcel from seller Tropicana Products. Tropicana bought the site in 1998 for $2.05 million, with future needs in mind.
“We're providing opportunity for the biotech support businesses and spinoffs and start-ups that maybe can't afford the pricey addresses or need more of a light industrial focus,” project attorney Bobby Klein told the newspaper.
Investors Seek New Life Sciences Users for 50,000 Square Feet in Lake Placid, NY
A trio of local investors is seeking life science users to reoccupy the 34-acre former Upstate Biotechnology property on Old Barn Road in Lake Placid, NY, which they purchased in June 2007, the Lake Placid News reported.
PEG Enterprises and partners Patrick Barrett, Edwin Weibrecht, and Greg Peacock are marketing the site’s 50,000-square-foot, two-story building, as well as a tennis court and several outbuildings. Barrett told the newspaper PEG is working on developing a Web site to outline the building and its attributes to potential renters: “We’ve kept it in good shape.”
The property was developed in the 1970s as the W. Alton Jones Cell Science Center, and later became Upstate Biotechnology. In 2004, Upstate Biologicals was acquired by Serologicals, which shut down the site, idling 140 employees.
SteriPack Expands by 50 Percent
SteriPack, a contract manufacturer of medical packaging products based in Offaly, Ireland, has announced plans to add 25,000 square feet growth to its existing 45,000-square-foot facility, to accommodate growth of more than 50 percent.
The firm currently supplies customers in more than 25 countries with both packaging and contract packaging services.
WaferGen Building R&D Center in Kedah, Malaysia
WaferGen Biosystems, a Silicon Valley-based biotech company, has opened its first overseas facility in Kulim Hi-Tech Park, Kedah, Malaysia.
The Malaysia Star reported last week that the R&D center was built for around 10 million Malaysia ringgits ($3.1 million).
Alnoor Shivji, WaferGen’s chairman and CEO, said the R&D center would be completed by April and would employ some 100 researchers and scientists, mainly from Indonesia, according to the newspaper. The facility will be overseen by WaferGen’s Malaysian unit, WaferGen Biosystems (M) Sdn Bhd.
WaferGen develops gene expression, genotyping, cell biology and stem cell research systems for the life science and pharmaceutical industries.
Shivji said the company would form collaborations with local universities, research institutions, and relevant supporting industries for research in biotechnology.
WaferGen Biosystems (M) signed a memorandum of agreement with Kulim Technology Park Corp. for the lease of office space and with KedahBio Resources Corp Sdn Bhd, a subsidiary of KTPC, for use of facilities.
It also signed a memorandum of understanding with Penang-based Pentamaster Corp Bhd for manufacturing and designing the required equipment.
KTPC group CEO Datuk Ahmad Shukri Tajuddin said WaferGen is the first biotech company to team up with KTPC to promote biotechnology activities in Kedah.